TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
32 hedge funds and large institutions have $18.8M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
1,817% more call options, than puts
Call options by funds: $115K | Put options by funds: $6K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
28% more capital invested
Capital invested by funds: $14.6M → $18.8M (+$4.17M)
3% more funds holding
Funds holding: 31 → 32 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$286K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$68.6K |
| 3 |
Renaissance Technologies
New York
|
+$55K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$37.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$70.3K |
| 2 |
VF
Virtu Financial
New York
|
-$67K |
| 3 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$14.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.49K |
| 5 |
BlackRock
New York
|
-$3.51K |
TCON Hedge Fund Activity: Q1 2023 in Review
32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2023, worth a combined $18.8M — up 28% from $14.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TCON positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Opaleye Management, adding an estimated $286K. The largest seller was Two Sigma Advisers, cutting an estimated $70.3K.
- 32 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2023, up from 31 in Q4 2022.
- Funds reported $18.8M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2023, up 28% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 3 closed out, a net change of +2 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Opaleye Management, an estimated $286K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Two Sigma Advisers, an estimated $70.3K sold.
Based on aggregated 13F filings for Q1 2023.